Differences
This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revision | ||
treatment_sodium_bicarbonate [2025/04/13 01:10] – [2.1 QRS Widening Secondary to Fast Sodium Channel Blockade] jkohts | treatment_sodium_bicarbonate [2025/04/16 04:26] (current) – [2.2 Salicylate Toxicity] jkohts | ||
---|---|---|---|
Line 2: | Line 2: | ||
===== - Overview ===== | ===== - Overview ===== | ||
+ | Sodium bicarbonate (NaHCO₃) is primarily used in toxicology to treat sodium channel blocker toxicity (e.g. TCA toxicity). | ||
- | + | The patient should then be [[concept_serum_alkalinization|hyperventilated]]. | |
- | Sodium Bicarbonate (NaHCO3) is the primary antidote for [[: | + | |
- | + | ||
- | The patient should then be [[: | + | |
Line 16: | Line 14: | ||
* Also see: Tricyclic antidepressants, | * Also see: Tricyclic antidepressants, | ||
* **Adult:** | * **Adult:** | ||
- | * 💊 **Sodium | + | * 💊 **Sodium |
* **Child:** | * **Child:** | ||
- | * 💊👶 **Sodium | + | * 💊👶 **Sodium |
* Repeat boluses until signs of cardiotoxicity (QRS widening, wide complex dysrhythmias) improve. | * Repeat boluses until signs of cardiotoxicity (QRS widening, wide complex dysrhythmias) improve. | ||
* Do not exceed serum pH 7.55, Na⁺ 155 mmol/L. | * Do not exceed serum pH 7.55, Na⁺ 155 mmol/L. | ||
Line 27: | Line 25: | ||
* Alkalinization therapy in salicylate toxicity works by ↓ CNS redistribution of salicylates (alters drug distribution), | * Alkalinization therapy in salicylate toxicity works by ↓ CNS redistribution of salicylates (alters drug distribution), | ||
* **Adult:** | * **Adult:** | ||
- | * 💊 **Sodium | + | * 💊 **Sodium |
- | * 💊 **Sodium | + | * 💊 **Sodium |
- | * e.g. 150 mmol of Sodium | + | * e.g. 150 mmol of Sodium |
* **Child:** | * **Child:** | ||
- | * 💊👶 **Sodium | + | * 💊👶 **Sodium |
- | * 💊👶 **Sodium | + | * 💊👶 **Sodium |
- | * Maintain normokalemia. | + | |
* Goals: | * Goals: | ||
* Serum pH 7.5-7.55. | * Serum pH 7.5-7.55. | ||
* Urinary pH >7.5. | * Urinary pH >7.5. | ||
* Urine output 2-3 mL/kg/hr. | * Urine output 2-3 mL/kg/hr. | ||
+ | * Maintain normokalemia. | ||
- | ==== - Indication 3 ==== | ||
- | * Also see: [[relevant pages]]. | + | ===== - Cautions & Contraindications ===== |
- | * **Adult:** 💊 **DrugName Dose Route**, Frequency. | + | |
- | * **Child:** 💊👶 **DrugName Dose Route**, Frequency. | + | |
- | * Other notes if applicable. | + | |
+ | * Metabolic or respiratory alkalosis - do not exceed pH 7.55. | ||
+ | * Severe hypernatremia - do not exceed Na⁺ 155 mmol/L. | ||
+ | * Hypokalemia. | ||
+ | * Acute pulmonary edema. | ||
- | ===== - Cautions & Contraindications ===== | ||
- | * Metabolic or respiratory alkalosis | ||
- | * Severe hypernatremia | ||
- | * Hypokalemia | ||
- | * Acute pulmonary edema | ||
===== - Special Populations ===== | ===== - Special Populations ===== | ||
- | **Pregnancy rating:** | ||
- | **Lactation:** | + | **Renal impairment:** Use with caution in patients with severe renal impairment due to the risk of fluid overload and hypernatremia. |
- | **Renal impairment: | ||
- | **Hepatic impairment:** | + | ===== - Adverse Effects ===== |
+ | | ||
+ | * **Metabolic: | ||
+ | * **Skin:** local phlebitis, cellulitis, extravasation injury. | ||
- | |||
- | ===== - Adverse Effects ===== | ||
- | * Description of important/ | ||
- | * Serotonin syndrome: | ||
- | * Systems e.g. | ||
- | * **GI:** | ||
- | * **Resp:** | ||
- | * **MSK:** local phlebitis | ||
- | * Frequency e.g. | ||
- | * **Common:** | ||
Line 79: | Line 63: | ||
==== - Pharmacodynamics ==== | ==== - Pharmacodynamics ==== | ||
- | **Mechanism of action:** | + | **Mechanism of action: |
==== - Pharmacokinetics ==== | ==== - Pharmacokinetics ==== | ||
+ | The pharmacokinetics of sodium bicarbonate are challenging to measure, as the bicarbonate component rapidly buffers H⁺ ions and is converted into CO₂. | ||
**Absorption: | **Absorption: | ||
- | * Oral bioavailability: | + | * Oral bioavailability: |
- | * GI tract absorption: | + | |
- | * First pass metabolism: | + | |
**Distribution: | **Distribution: | ||
- | * Vd: | + | * Vd: 0.2-0.4 L/kg. |
- | * Lipid solubility: | + | |
- | * Crosses/Does not cross BBB | + | |
- | * Crosses/ | + | |
- | * Excreted/ | + | |
- | * Protein binding: | + | |
- | * Tmax: | + | |
**Metabolism: | **Metabolism: | ||
+ | * Reacts with H⁺ to form H₂O and CO₂. | ||
+ | * Bicarbonate contributes to 80% of extracellular buffering capacity. | ||
**Excretion: | **Excretion: | ||
- | * Elimination t½: | + | * CO₂ is exhaled. |
- | * Hepatic clearance: | + | * Bicarbonate and Na⁺ is excreted renally. |
- | * Renal clearance: | + | |
==== - Pharmaceutics ==== | ==== - Pharmaceutics ==== | ||
- | **Formulation: | + | **Formulation: |